Supernus Pharmaceuticals (SUPN) Cash & Current Investments (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Cash & Current Investments of $372.1 million for Q2 2026, down 28.8% year-over-year from $522.6 million in Q2 2025, and down 3.17% on a QoQ basis from $384.2 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Cash & Current Investments (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Cash & Current Investments for 16 years, with the latest figure at $372.1 million in Q2 2026.
- Cash & Current Investments for Q2 2026 came in at $372.1 million, down 28.8% year-over-year; the trailing twelve-month figure through Jun 2026 was $372.1 million (down 28.8% YoY), and the FY2025 annual result was $308.7 million, down 31.95% from the prior year.
- Cash & Current Investments slipped to $372.1 million in Q2 2026, from $384.2 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $522.6 million in Q2 2025 and troughed at $151.7 million in Q2 2023.
- A 5-year average of $344.2 million and a median of $354.0 million in 2022 frame the typical range for Cash & Current Investments.
- The widest annual swing landed in 2023, when Cash & Current Investments tumbled 57.97%; it then soared 128.93% in 2024.
- A 5-year view of Cash & Current Investments shows it stood at $461.3 million in 2022, then sank by 44.75% to $254.9 million in 2023, then jumped by 77.97% to $453.6 million in 2024, then plunged by 31.95% to $308.7 million in 2025, then rose by 20.54% to $372.1 million in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $372.1 million in Q2 2026, $384.2 million in Q1 2026, and $308.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn | 372.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 372.07 Mn |
| Mar 31, 2026 | 384.24 Mn |
| Dec 31, 2025 | 308.67 Mn |
| Sep 30, 2025 | 281.16 Mn |
| Jun 30, 2025 | 522.60 Mn |
| Mar 31, 2025 | 463.59 Mn |
| Dec 31, 2024 | 453.61 Mn |
| Sep 30, 2024 | 403.21 Mn |
| Jun 30, 2024 | 347.19 Mn |
| Mar 31, 2024 | 297.74 Mn |
| Dec 31, 2023 | 254.87 Mn |
| Sep 30, 2023 | 200.19 Mn |
| Jun 30, 2023 | 151.66 Mn |
| Mar 31, 2023 | 228.57 Mn |
| Dec 31, 2022 | 461.33 Mn |
| Sep 30, 2022 | 391.79 Mn |
| Jun 30, 2022 | 360.79 Mn |
| Mar 31, 2022 | 312.20 Mn |
| Dec 31, 2021 | 339.68 Mn |
| Sep 30, 2021 | 443.85 Mn |